EUVIMEDEUVIMED entdecken
Open Access

Association Between Drug Characteristics and Manufacturer Spending on Direct-to-Consumer Advertising

Michael J DiStefano, Jenny M Markell, Caroline C Doherty, G Caleb Alexander, Gerard F Anderson

JAMA · 07.02.2023 · 329 (5) · 386

DOI: 10.1001/jama.2022.23968 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, erschienen am 07.02.2023. Verfasst von Michael J DiStefano und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. Hauptthemen laut MEDLINE: Direct-to-Consumer Advertising, Pharmaceutical Preparations, Drug Industry. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: AHRQ HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Some drugs are heavily marketed through direct-to-consumer advertising.

Objective

To identify drug characteristics associated with a greater share of promotional spending on advertising directly to consumers. Design, Setting, and Participants Exploratory cross-sectional analysis of drug characteristics and promotional spending for the 150 top-selling branded prescription drugs in the US in 2020 as identified from IQVIA National Sales Perspectives data. Promotional spending data were provided by IQVIA ChannelDynamics. Exposures Drug characteristics (total 2020 sales; total 2020 promotional spending; clinical benefit ratings; number of indications, off-label use; molecule type; nature of condition treated; administration type; generic availability; US Food and Drug Administration [FDA] approval year, World Health Organization anatomical therapeutic chemical classification; Medicare annual mean spending per beneficiary; percent sales attributable to the drug; market size; market competitiveness) assessed from health technology assessment agencies (France’s Haute Autorité de Santé and Canada’s Patented Medicine Prices Review Board) and drug data sources (Drugs@FDA, the FDA Purple Book, Lexicomp, Merative Marketscan Research Databases, and Medicare Spending by Drug data). Main Outcomes and Measures Proportion of total promotional spending allocated to direct-to-consumer-advertising for each drug.

Results

The 2020 median proportion of promotional spending allocated to direct-to-consumer advertising was 13.5% (IQR, 1.96%-36.6%); median promotional spending, $20.9 million (IQR, $2.72-$131 million); and median total sales, $1.51 billion (IQR, $0.97-$2.26 billion). Of the 150 best-selling drugs, 16 were missing data and key covariates; therefore, the primary study sample comprised 134 drugs. After adjustment for multiple drug characteristics, the mean proportion of total promotional spending allocated to direct-to-consumer advertising for the remaining 134 drugs was an absolute 14.3% (95% CI, 1.43%-27.2%; P = .03) higher for those with low added clinical benefit than for those with high added clinical benefit and an absolute 1.5% (95% CI, 0.44%-2.56%; P = .005) higher for each 10% increase in total sales. Conclusions and Relevance Among top-selling US drugs in 2020, a rating of lower added benefit and higher total drug sales were associated with a higher proportion of manufacturer total promotional spending allocated to direct-to-consumer advertising. Further research is needed to understand the implications of these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Direct-to-Consumer AdvertisingPharmaceutical PreparationsDrug IndustryCross-Sectional StudiesNational Health ProgramsUnited States

Substanzen

Pharmaceutical Preparations

Autor:innen und Institutionen

  • Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
  • Berman Institute of Bioethics, Johns Hopkins University, Baltimore, Maryland.
  • Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
  • Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

Förderung

  • AHRQ HHS

Zitieren

APA

DiStefano, M. J., Markell, J. M., Doherty, C. C., Alexander, G. C., & Anderson, G. F. (2023). Association Between Drug Characteristics and Manufacturer Spending on Direct-to-Consumer Advertising. JAMA, 329(5), 386. https://doi.org/10.1001/jama.2022.23968

Vancouver

DiStefano MJ, Markell JM, Doherty CC, Alexander GC, Anderson GF. Association Between Drug Characteristics and Manufacturer Spending on Direct-to-Consumer Advertising. JAMA. 2023;329(5):386. doi:10.1001/jama.2022.23968

BibTeX
@article{DiStefano2023,
  author = {DiStefano, Michael J and Markell, Jenny M and Doherty, Caroline C and Alexander, G Caleb and Anderson, Gerard F},
  title = {Association Between Drug Characteristics and Manufacturer Spending on Direct-to-Consumer Advertising},
  journal = {JAMA},
  year = {2023},
  volume = {329},
  number = {5},
  pages = {386},
  doi = {10.1001/jama.2022.23968}
}
Kostenlos starten →